A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities
Crossref DOI link: https://doi.org/10.1007/s00280-015-2931-4
Published Online: 2016-01-25
Published Print: 2016-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lu, Dan
Lu, Tong
Stroh, Mark
Graham, Richard A.
Agarwal, Priya
Musib, Luna
Li, Chi-Chung
Lum, Bert L.
Joshi, Amita
License valid from 2016-01-25